Song Pharmaceutical: The first batch of subjects in the 13-week Phase IIa study of small-molecule oral GLP-1R agonist ASC30 in the United States has completed dosing.

Gaoli Pharmaceutical announced on the Hong Kong Stock Exchange that the first batch of obese or overweight subjects has been dosed with the small molecule oral GLP-1R agonist ASC30 in a 13-week Phase IIa study in the United States. In the Phase Ib study in the United States, ASC30 once-daily oral tablets showed up to a 6.5% decrease in average body weight from the baseline after 4 weeks of treatment with placebo calibration. The top-line data from the ASC30 oral 13-week Phase IIa study is expected to be obtained in the fourth quarter of 2025.